IBDEI1LW ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4)
;;=^IBE(358.4,
;;^UTILITY(U,$J,358.4,0)
;;=IMP/EXP SELECTION GROUP^358.4I^1190^1190
;;^UTILITY(U,$J,358.4,1,0)
;;=NEW PATIENT^2^1
;;^UTILITY(U,$J,358.4,2,0)
;;=ESTABLISHED PATIENT^1^1
;;^UTILITY(U,$J,358.4,3,0)
;;=CONSULTATIONS^3^1
;;^UTILITY(U,$J,358.4,4,0)
;;=ALLERGY DIAGNOSES^1^2
;;^UTILITY(U,$J,358.4,5,0)
;;=IMMUNODEFICIENCY^2^2
;;^UTILITY(U,$J,358.4,6,0)
;;=OTHER^3^2
;;^UTILITY(U,$J,358.4,7,0)
;;=IMMUNIZATION^4^3
;;^UTILITY(U,$J,358.4,8,0)
;;=SKIN TEST^9^3
;;^UTILITY(U,$J,358.4,9,0)
;;=ALLERGENIC EXTRACT^1^3
;;^UTILITY(U,$J,358.4,10,0)
;;=PATCH TESTS^8^3
;;^UTILITY(U,$J,358.4,11,0)
;;=ALLERGY INJECTION/EXTRACT^2^3
;;^UTILITY(U,$J,358.4,12,0)
;;=LABORATORY^6^3
;;^UTILITY(U,$J,358.4,13,0)
;;=INFUSIONS^5^3
;;^UTILITY(U,$J,358.4,14,0)
;;=OTHER^7^3
;;^UTILITY(U,$J,358.4,15,0)
;;=SPECIAL SERVICES^7^4
;;^UTILITY(U,$J,358.4,16,0)
;;=TREATMENT^8^4
;;^UTILITY(U,$J,358.4,17,0)
;;=MISCELLANEOUS^4^4
;;^UTILITY(U,$J,358.4,18,0)
;;=IMMUNIZATIONS^3^4
;;^UTILITY(U,$J,358.4,19,0)
;;=CHEMO ADMINISTRATION^1^4
;;^UTILITY(U,$J,358.4,20,0)
;;=CHEMO DRUGS^2^4
;;^UTILITY(U,$J,358.4,21,0)
;;=OTHER DRUGS^5^4
;;^UTILITY(U,$J,358.4,22,0)
;;=PROLONGED SERVICES^6^4
;;^UTILITY(U,$J,358.4,23,0)
;;=NEW PATIENT^2^5
;;^UTILITY(U,$J,358.4,24,0)
;;=ESTABLISHED PATIENT^1^5
;;^UTILITY(U,$J,358.4,25,0)
;;=CONSULTATIONS^3^5
;;^UTILITY(U,$J,358.4,26,0)
;;=POST OP^4^5
;;^UTILITY(U,$J,358.4,27,0)
;;=ANEMIA^2^6
;;^UTILITY(U,$J,358.4,28,0)
;;=BREAST & GYN NEOPLASMS^2^6
;;^UTILITY(U,$J,358.4,29,0)
;;=COAGULATION DISORDERS^3^6
;;^UTILITY(U,$J,358.4,30,0)
;;=COUNSELING & SCREENING^4^6
;;^UTILITY(U,$J,358.4,31,0)
;;=GENITOURINARY NEOPLASMS^5^6
;;^UTILITY(U,$J,358.4,32,0)
;;=GI CANCER^6^6
;;^UTILITY(U,$J,358.4,33,0)
;;=HEAD/NECK/LUNG CANCER^7^6
;;^UTILITY(U,$J,358.4,34,0)
;;=HEMOGLOBINOPATHIES^9^6
;;^UTILITY(U,$J,358.4,35,0)
;;=LYMPHOID NEOPLASMS^10^6
;;^UTILITY(U,$J,358.4,36,0)
;;=METASTATIC SITES^11^6
;;^UTILITY(U,$J,358.4,37,0)
;;=MISC. NEOPLASMS^12^6
;;^UTILITY(U,$J,358.4,38,0)
;;=MYELOID NEOPLASMS/DISORDERS^13^6
;;^UTILITY(U,$J,358.4,39,0)
;;=PERSONAL HX OF CANCER^15^6
;;^UTILITY(U,$J,358.4,40,0)
;;=OTHER^14^6
;;^UTILITY(U,$J,358.4,41,0)
;;=HEMATOLOGICAL^8^6
;;^UTILITY(U,$J,358.4,42,0)
;;=SYMPTOMS^17^6
;;^UTILITY(U,$J,358.4,43,0)
;;=TREATMENT^18^6
;;^UTILITY(U,$J,358.4,44,0)
;;=SUICIDE IDEATIONS/ATTEMPTS^16^6
;;^UTILITY(U,$J,358.4,45,0)
;;=ABNORMAL LAB TEST RESULTS^1^6
;;^UTILITY(U,$J,358.4,46,0)
;;=SPECIAL SERVICES^10^7
;;^UTILITY(U,$J,358.4,47,0)
;;=CHEMO NURSE PROCEDURES^2^7
;;^UTILITY(U,$J,358.4,48,0)
;;=INFUSION DRUGS^7^7
;;^UTILITY(U,$J,358.4,49,0)
;;=BLOOD PRODUCTS^1^7
;;^UTILITY(U,$J,358.4,50,0)
;;=DIAGNOSTIC PROCEDURES^3^7
;;^UTILITY(U,$J,358.4,51,0)
;;=OTHER DRUGS^8^7
;;^UTILITY(U,$J,358.4,52,0)
;;=IMMUNIZATION ADMINISTRATION^5^7
;;^UTILITY(U,$J,358.4,53,0)
;;=IMMUNIZATIONS^6^7
;;^UTILITY(U,$J,358.4,54,0)
;;=PROLONGED SVC-MD/NP/PA^9^7
;;^UTILITY(U,$J,358.4,55,0)
;;=EDUCATION/TRAINING^4^7
;;^UTILITY(U,$J,358.4,56,0)
;;=NEW PATIENT^2^8
;;^UTILITY(U,$J,358.4,57,0)
;;=ESTABLISHED PATIENT^1^8
;;^UTILITY(U,$J,358.4,58,0)
;;=CONSULTATIONS^3^8
;;^UTILITY(U,$J,358.4,59,0)
;;=COMPLEX CHRONIC CARE^4^8
;;^UTILITY(U,$J,358.4,60,0)
;;=ANEMIA^1^9
;;^UTILITY(U,$J,358.4,61,0)
;;=ARTIFICIAL OPENING STATUS^2^9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1LW 3750 printed Sep 23, 2025@19:47:17 Page 2
IBDEI1LW ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4)
+2 ;;=^IBE(358.4,
+3 ;;^UTILITY(U,$J,358.4,0)
+4 ;;=IMP/EXP SELECTION GROUP^358.4I^1190^1190
+5 ;;^UTILITY(U,$J,358.4,1,0)
+6 ;;=NEW PATIENT^2^1
+7 ;;^UTILITY(U,$J,358.4,2,0)
+8 ;;=ESTABLISHED PATIENT^1^1
+9 ;;^UTILITY(U,$J,358.4,3,0)
+10 ;;=CONSULTATIONS^3^1
+11 ;;^UTILITY(U,$J,358.4,4,0)
+12 ;;=ALLERGY DIAGNOSES^1^2
+13 ;;^UTILITY(U,$J,358.4,5,0)
+14 ;;=IMMUNODEFICIENCY^2^2
+15 ;;^UTILITY(U,$J,358.4,6,0)
+16 ;;=OTHER^3^2
+17 ;;^UTILITY(U,$J,358.4,7,0)
+18 ;;=IMMUNIZATION^4^3
+19 ;;^UTILITY(U,$J,358.4,8,0)
+20 ;;=SKIN TEST^9^3
+21 ;;^UTILITY(U,$J,358.4,9,0)
+22 ;;=ALLERGENIC EXTRACT^1^3
+23 ;;^UTILITY(U,$J,358.4,10,0)
+24 ;;=PATCH TESTS^8^3
+25 ;;^UTILITY(U,$J,358.4,11,0)
+26 ;;=ALLERGY INJECTION/EXTRACT^2^3
+27 ;;^UTILITY(U,$J,358.4,12,0)
+28 ;;=LABORATORY^6^3
+29 ;;^UTILITY(U,$J,358.4,13,0)
+30 ;;=INFUSIONS^5^3
+31 ;;^UTILITY(U,$J,358.4,14,0)
+32 ;;=OTHER^7^3
+33 ;;^UTILITY(U,$J,358.4,15,0)
+34 ;;=SPECIAL SERVICES^7^4
+35 ;;^UTILITY(U,$J,358.4,16,0)
+36 ;;=TREATMENT^8^4
+37 ;;^UTILITY(U,$J,358.4,17,0)
+38 ;;=MISCELLANEOUS^4^4
+39 ;;^UTILITY(U,$J,358.4,18,0)
+40 ;;=IMMUNIZATIONS^3^4
+41 ;;^UTILITY(U,$J,358.4,19,0)
+42 ;;=CHEMO ADMINISTRATION^1^4
+43 ;;^UTILITY(U,$J,358.4,20,0)
+44 ;;=CHEMO DRUGS^2^4
+45 ;;^UTILITY(U,$J,358.4,21,0)
+46 ;;=OTHER DRUGS^5^4
+47 ;;^UTILITY(U,$J,358.4,22,0)
+48 ;;=PROLONGED SERVICES^6^4
+49 ;;^UTILITY(U,$J,358.4,23,0)
+50 ;;=NEW PATIENT^2^5
+51 ;;^UTILITY(U,$J,358.4,24,0)
+52 ;;=ESTABLISHED PATIENT^1^5
+53 ;;^UTILITY(U,$J,358.4,25,0)
+54 ;;=CONSULTATIONS^3^5
+55 ;;^UTILITY(U,$J,358.4,26,0)
+56 ;;=POST OP^4^5
+57 ;;^UTILITY(U,$J,358.4,27,0)
+58 ;;=ANEMIA^2^6
+59 ;;^UTILITY(U,$J,358.4,28,0)
+60 ;;=BREAST & GYN NEOPLASMS^2^6
+61 ;;^UTILITY(U,$J,358.4,29,0)
+62 ;;=COAGULATION DISORDERS^3^6
+63 ;;^UTILITY(U,$J,358.4,30,0)
+64 ;;=COUNSELING & SCREENING^4^6
+65 ;;^UTILITY(U,$J,358.4,31,0)
+66 ;;=GENITOURINARY NEOPLASMS^5^6
+67 ;;^UTILITY(U,$J,358.4,32,0)
+68 ;;=GI CANCER^6^6
+69 ;;^UTILITY(U,$J,358.4,33,0)
+70 ;;=HEAD/NECK/LUNG CANCER^7^6
+71 ;;^UTILITY(U,$J,358.4,34,0)
+72 ;;=HEMOGLOBINOPATHIES^9^6
+73 ;;^UTILITY(U,$J,358.4,35,0)
+74 ;;=LYMPHOID NEOPLASMS^10^6
+75 ;;^UTILITY(U,$J,358.4,36,0)
+76 ;;=METASTATIC SITES^11^6
+77 ;;^UTILITY(U,$J,358.4,37,0)
+78 ;;=MISC. NEOPLASMS^12^6
+79 ;;^UTILITY(U,$J,358.4,38,0)
+80 ;;=MYELOID NEOPLASMS/DISORDERS^13^6
+81 ;;^UTILITY(U,$J,358.4,39,0)
+82 ;;=PERSONAL HX OF CANCER^15^6
+83 ;;^UTILITY(U,$J,358.4,40,0)
+84 ;;=OTHER^14^6
+85 ;;^UTILITY(U,$J,358.4,41,0)
+86 ;;=HEMATOLOGICAL^8^6
+87 ;;^UTILITY(U,$J,358.4,42,0)
+88 ;;=SYMPTOMS^17^6
+89 ;;^UTILITY(U,$J,358.4,43,0)
+90 ;;=TREATMENT^18^6
+91 ;;^UTILITY(U,$J,358.4,44,0)
+92 ;;=SUICIDE IDEATIONS/ATTEMPTS^16^6
+93 ;;^UTILITY(U,$J,358.4,45,0)
+94 ;;=ABNORMAL LAB TEST RESULTS^1^6
+95 ;;^UTILITY(U,$J,358.4,46,0)
+96 ;;=SPECIAL SERVICES^10^7
+97 ;;^UTILITY(U,$J,358.4,47,0)
+98 ;;=CHEMO NURSE PROCEDURES^2^7
+99 ;;^UTILITY(U,$J,358.4,48,0)
+100 ;;=INFUSION DRUGS^7^7
+101 ;;^UTILITY(U,$J,358.4,49,0)
+102 ;;=BLOOD PRODUCTS^1^7
+103 ;;^UTILITY(U,$J,358.4,50,0)
+104 ;;=DIAGNOSTIC PROCEDURES^3^7
+105 ;;^UTILITY(U,$J,358.4,51,0)
+106 ;;=OTHER DRUGS^8^7
+107 ;;^UTILITY(U,$J,358.4,52,0)
+108 ;;=IMMUNIZATION ADMINISTRATION^5^7
+109 ;;^UTILITY(U,$J,358.4,53,0)
+110 ;;=IMMUNIZATIONS^6^7
+111 ;;^UTILITY(U,$J,358.4,54,0)
+112 ;;=PROLONGED SVC-MD/NP/PA^9^7
+113 ;;^UTILITY(U,$J,358.4,55,0)
+114 ;;=EDUCATION/TRAINING^4^7
+115 ;;^UTILITY(U,$J,358.4,56,0)
+116 ;;=NEW PATIENT^2^8
+117 ;;^UTILITY(U,$J,358.4,57,0)
+118 ;;=ESTABLISHED PATIENT^1^8
+119 ;;^UTILITY(U,$J,358.4,58,0)
+120 ;;=CONSULTATIONS^3^8
+121 ;;^UTILITY(U,$J,358.4,59,0)
+122 ;;=COMPLEX CHRONIC CARE^4^8
+123 ;;^UTILITY(U,$J,358.4,60,0)
+124 ;;=ANEMIA^1^9
+125 ;;^UTILITY(U,$J,358.4,61,0)
+126 ;;=ARTIFICIAL OPENING STATUS^2^9
